T cell activation and senescence predict subclinical carotid artery disease in HIV-infected women.

Permalink
https://escholarship.org/uc/item/7j197390

Journal
The Journal of infectious diseases, 203(4)

ISSN
0022-1899

Authors
Kaplan, Robert C
Sinclair, Elizabeth
Landay, Alan L
et al.

Publication Date
2011-02-01

DOI
10.1093/infdis/jiq071

Peer reviewed
T Cell Activation and Senescence Predict Subclinical Carotid Artery Disease in HIV-Infected Women

Robert C. Kaplan,1 Elizabeth Sinclair,2 Alan L. Landay,4 Nell Lurain,4 A. Richey Sharrett,5 Stephen J. Gange,5 Xiaonan Xue,1 Peter Hunt,2 Roksana Karim,3 David M. Kern,1 Howard N. Hodis,3 and Steven G. Deeks2

1Department of Epidemiology and Population Health, Albert Einstein College of Medicine of Yeshiva University, Bronx, New York; 2Division of Experimental Medicine, University of California, San Francisco, and 3Atherosclerosis Research Unit, Departments of Medicine and Preventive Medicine, University of Southern California, Los Angeles, California; 4Rush University Medical Center, Chicago, Illinois; and 5Johns Hopkins Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland

Background. Individuals infected with human immunodeficiency virus (HIV) have increased risk of cardiovascular events. It is unknown whether T cell activation and senescence, 2 immunologic sequelae of HIV infection, are associated with vascular disease among HIV-infected adults.

Methods. T cell phenotyping and carotid ultrasound were assessed among 115 HIV-infected women and 43 age- and race/ethnicity-matched HIV-uninfected controls participating in the Women’s Interagency HIV Study. Multivariate analyses were used to assess the association of T cell activation (CD38+HLA-DR+) and senescence (CD28−CD57+) with subclinical carotid artery disease.

Results. Compared with HIV-uninfected women, frequencies of CD4+CD38+HLA-DR+, CD8+CD38+HLA-DR+, and CD8+CD28−CD57+ T cells were higher among HIV-infected women, including those who achieved viral suppression while receiving antiretroviral treatment. Among HIV-infected women, adjusted for age, antiretroviral medications, and viral load, higher frequencies of activated CD4+ and CD8+ T cells and immunosenescent CD8+ T cells were associated with increased prevalence of carotid artery lesions (prevalence ratiolesions associated with activated CD4+ T cells, 1.6 per SD [95% confidence interval {CI}, 1.1–2.2]; P = .02; prevalence ratiolesions associated with activated CD8+ T cells, 2.0 per SD [95% CI, 1.2–3.3]; P < .01; prevalence ratiolesions associated with senescent CD8+ T cells, 1.9 per SD [95% CI, 1.1–3.1]; P = .01).

Conclusions. HIV-associated T cell changes are associated with subclinical carotid artery abnormalities, which may be observed even among those patients achieving viral suppression with effective antiretroviral therapy.

As compared with control individuals without human immunodeficiency virus (HIV) infection, HIV-infected patients have increased risk of acute cardiovascular disease (CVD) events including myocardial infarction [1] and advanced subclinical vascular disease [2]. The CVD risk associated with HIV infection appears to be partially attenuated by antiretroviral treatment, since treatment interruption increases short-term risk of CVD events [3]. Although effective HIV therapy appears to reduce the risk of CVD, it may not fully reverse HIV-associated vascular risk, and long-term exposure to HIV therapy may have direct adverse effects on CVD [4].

The mechanism for increased CVD risk in antiretroviral-treated and untreated HIV infection is likely multifactorial, involving pathways related to traditional vascular risk factors and antiretroviral drug toxicities. Chronic inflammation, which is a well-accepted CVD risk factor in the non-HIV setting, may also be important. Many markers of inflammation, including T cell activation as defined by co-expression of CD38 and HLA-DR, are markedly elevated in individuals with
untreated HIV infection and are only partially reversed by effective combination antiretroviral therapy [5, 6]. The frequency of activated CD8\(^{+}\) T cells predicts the risk of disease progression independent of other factors in untreated HIV infection [7] and is consistently associated with immunologic and perhaps clinical outcomes in the context of antiretroviral-treated infection [6]. The role of activated T cells and their inflammatory products in atherosclerosis has been well studied [8], although whether vascular changes in HIV-infected patients are influenced by systemic T cell activation remains uncertain.

There is a growing body of literature suggesting that chronic viral infections cause accelerated aging of the immune system (called “immunosenescence”). For example, cytomegalovirus (CMV) infection is associated with oligoclonal expansion of terminally differentiated T cells, decreased T cell repertoire, lower T cell proliferation rates, and increased levels of a number of inflammatory markers [9]. Untreated HIV infection produces a number of these same phenotypic and functional changes to the immune system [10]. More recently, evidence has emerged to suggest that immune senescence driven by responses to chronic infection may play a role in heart and vascular diseases [11].

Given the evidence that HIV infection is associated with increased levels of immune activation, inflammation, and immunosenescence, we conducted a study to address the hypothesis that these pathways mediate the association of HIV infection with vascular disease. Archived specimens from a well-characterized longitudinal US cohort of HIV-infected and HIV-uninfected women were used to measure cell surface expression of CD38, HLA-DR, CD28, and CD57 on CD4\(^{+}\) and CD8\(^{+}\) T cells. We then related activation (CD38\(^{+}\)HLA-DR\(^{+}\)) and senescent (CD28\(^{-}\)CD57\(^{-}\)) T cell subsets with subclinical vascular disease as assessed by B-mode carotid artery ultrasound.

**METHODS**

**Study Population**

This study was conducted among participants in the Women’s Interagency HIV Study (WIHS), a prospective multicenter study. Participants were recruited in 2 waves (in 1994–1995 and 2001–2002) and completed study visits every 6 months. In April 2004, a carotid ultrasound substudy was initiated which included B-mode ultrasound imaging of the carotid arteries. For the present investigation, we conducted T cell phenotyping among 115 HIV-infected women who were \(\geq 40\) years of age at the time of their carotid artery ultrasound scan and free of clinical vascular disease. A group of HIV-uninfected women \((n = 43)\) was also selected who were frequency-matched to the HIV-infected individuals by age (\(\pm 5\) years) and race/ethnicity. The HIV-infected and HIV-uninfected groups had comparable demographic and socioeconomic characteristics and were recruited using similar methods. Institutional review board approval and informed consent were obtained.

**Carotid Artery Ultrasound**

High-resolution B-mode carotid artery ultrasound was used to image the right common carotid artery, internal carotid artery, and carotid bifurcation [12]. Right distal common carotid artery intima-media thickness (cIMT) was measured. The presence of carotid lesions was defined as a focal intima-media thickness of \(>1.5\) mm in any of the imaged segments. Standardized carotid artery ultrasound images were centrally measured by automated computerized edge detection by use of a software package developed in-house (Prowin patent, 2005, 2006).

**Assays**

HIV infection was determined via serologic testing using enzyme-linked immunosorbent assay (ELISA) and confirmed using Western blot assays. Plasma HIV RNA levels were quantified using nucleic-acid-sequence-based amplification commercial assays with a lower limit of quantification of 80 copies/mL (bioMérieux), and total peripheral CD4\(^{+}\) T cell counts were measured with standard flow cytometric methods. T cell activation and senescence were measured by immunophenotyping performed at the University of California, San Francisco, Core Immunology Laboratory, using methods that have been optimized and validated for frozen peripheral blood mononuclear cells (PBMCs). Cryopreserved PBMCs were rapidly thawed in warm medium, washed, stained with Viacount (Millipore), and run on a Guava PCA (Millipore) to determine cell number and viability. Samples with viability of \(<40\%\) were not analyzed. PBMCs were stained with aqua amine reactive dye (Invitrogen) to exclude nonviable cells and for surface expression of CD3, CD28 (BD Pharmingen), CD4, CD38, HLA-DR (BD Biosciences), CD8 (Invitrogen), and CD57 (Biolegend). Stained cells were run on a customized BD LSR II and data analyzed using FlowJo software, version 8.8.4 (Tree Star) to quantitate CD4\(^{+}\) and CD8\(^{+}\) T cells expressing activation (CD38 and HLA-DR) and senescence (CD28\(^{-}\) and CD57\(^{-}\)) markers (Figure 1). Data on CD38\(^{+}\)HLA-DR\(^{+}\) and CD28\(^{-}\)CD57\(^{-}\) subsets were expressed as the percentage of T cells expressing these markers.

**Clinical Variables**

Key cardiovascular and HIV-related covariates were obtained by self-report and direct measurements. We defined highly active antiretroviral therapy (HAART) in accordance with US Department of Health and Human Services guidelines.

**Data Analyses**

HIV-infected women were stratified as (1) untreated, (2) HAART-treated aviremic, or (3) treated with detectable viremia. Primary analyses examined carotid artery lesions and cIMT in relation to contemporaneous measures of T cell activation (CD38\(^{+}\)HLA-DR\(^{+}\)) and T cell senescence (CD28\(^{-}\)CD57\(^{-}\)).
define CD4 fluorescence-activated cell-sorting plots showing gating of T cells to HIV-infected women (RESULTS analyses stratified by presence or absence of HIV infection. infected and HIV-uninfected groups and also conducted included interaction terms in models that included both HIV-carotid artery disease was modified by HIV infection, we Subsequent models examined the potential confounding effects of cardiovascular risk factors, socioeconomic factors, and use of cigarettes, alcohol, and injection drugs. To assess whether the nature of associations between T cell phenotypes and subclinical carotid artery disease was modified by HIV infection, we included interaction terms in models that included both HIV-infected and HIV-uninfected groups and also conducted analyses stratified by presence or absence of HIV infection.

**RESULTS**

HIV-infected women ($n = 115$) and HIV-uninfected women ($n = 43$) were comparable in age (mean age of HIV-infected women, 46 years; mean age of HIV-uninfected women, 47 years) and race/ethnicity (63% and 67% of HIV-infected and HIV-uninfected women were African American, respectively, and 28% and 23% of HIV-infected and HIV-uninfected women were Hispanic, respectively) (Table 1). Among HIV-infected women, 36% were not currently receiving antiretroviral treatment, 39% were treated and had detectable viremia, and 25% were treated and had undetectable viremia. As compared with the overall WIHS cohort, the HIV-infected women in our study were slightly younger, were less likely to be non-Hispanic white, and had higher current viral load, but they did not otherwise differ significantly ($P < .05$) on variables shown in Table 1.

**T Cell Activation Markers**

Compared with HIV-uninfected women, HIV-infected women had markedly higher levels of CD4$^+$ and CD8$^+$ T cell activation ($P < .01$) (Table 1 and Figure 2). These differences remained significant when we restricted the HIV-infected group to those who were treated with HAART and had achieved viral suppression. Correlates of higher T cell activation included race/ethnicity, lower high-density lipoprotein cholesterol level, lower CD4$^+$ T cell count, lower ratio of CD4$^+$ T cells to CD8$^+$ T cells, and higher viral load (Table 2).

**T Cell Senescence Markers**

In comparison with HIV-uninfected controls, the percentage of CD8$^+$ T cells with an immunosenescence phenotype (CD28$^-$CD57$^+$) was increased among the HIV-infected women ($P < .01$) (Table 1 and Figure 2). This difference persisted even among HIV-infected women who were receiving HAART and who had undetectable HIV RNA levels. Correlates of CD8$^-$CD28$^-$CD57$^+$ T cells included race/ethnicity, smoking, and high-density lipoprotein cholesterol but not CD4$^+$ T cell count or plasma HIV RNA level (Table 2).

**CD38$^+$HLA-DR$^+$ T Cells and Subclinical Carotid Artery Disease**

Among the group of HIV-infected women, 19 had ≥1 carotid lesions whereas 96 had no carotid lesions. HIV-infected women with carotid lesions had a significantly higher percentage of CD4$^+$ T cells expressing activation markers (CD38$^+$HLA-DR$^+$) than those HIV-infected women without carotid lesions ($P = .02$) (Figure 3). The percentage of CD8$^+$ T cells expressing activation markers was also higher in HIV-infected women with lesions than that among HIV-infected women without lesions ($P = .04$) (Figure 3).

In adjusted models, among HIV-infected women, the prevalence of carotid lesions was directly associated with the percentage of CD4$^+$ and CD8$^+$ T cells expressing activation markers. Adjusted for age and antiretroviral medication use, the prevalence ratio$_{lesions}$ was 1.6 per SD change in the percentage of CD4$^+$CD38$^+$HLA-DR$^+$ T cells (95% confidence interval [CI], 1.1–2.2; $P = .02$), and the prevalence ratio$_{lesions}$ was 2.0 per SD change in the percentage of CD8$^+$CD38$^+$HLA-DR$^+$ T cells (95% CI, 1.2–3.3; $P < .01$) (Table 3). This association persisted...
Table 1. Characteristics of Human Immunodeficiency Virus (HIV)–Infected and HIV-Uninfected Women in the Women's Interagency HIV Study

| Characteristics | HIV-uninfected women | HIV-infected women | All | P, HIV-uninfected vs all HIV-infected women | P across HIV-uninfected and 3 HIV-infected groups |
|-----------------|----------------------|--------------------|-----|---------------------------------------------|-----------------------------------------------|
|                 | (N = 43)             | (N = 41)           | (N = 45) | (N = 115) |                                               |
| Age, years      | Median 47, IQR 8     | Median 47, IQR 8   | Median 47, IQR 7 | Median 46, IQR 6 | .91                                           |
| Laboratory variables |                   |                    |                   |                   | .34                                           |
| CD4⁺CD38⁺DR⁺ T cells, % | 2.5, 1.5          | 1.8, 3.8           | 3.1, 2.9          | 2.5, 3.9          | <.01                                          |
| CD8⁺CD38⁺DR⁺ T cells, % | 7.3, 8.9          | 7.4, 5.6           | 7.1, 7.9          | 7.7, 4.3          | <.01                                          |
| CD4⁺CD32⁻CD57⁺ T cells, % | 1.8, 4.4          | 2.9, 5.6           | 3.1, 9.4          | 2.5, 5.9          | .07                                           |
| CD8⁺CD28⁻CD57⁺ T cells, % | 22.7, 27.3       | 37.3, 21.9         | 36.9, 19.5        | 35.8, 21.7        | <.01                                          |
| Current viral load, copies/mL | NA ...           | 80, 0              | 4050, 25,575      | 5500, 20,680      | <.01                                          |
| Peak viral load, ×1000 copies/mL | NA ...         | 110, 330           | 24, 83.6          | 160, 343          | NA <.01                                       |
| Current CD4 cell count, cells/μL | 782, 236       | 327, 297           | 209, 236          | NA ...            | .91                                           |
| Nadir CD4 cell count, cells/μL | 100, 31          | 9, 16              | 16, 33            | NA ...            | <.01                                          |
| CD4/CD8 ratio of >1, % | 100 ...          | 12, 9              | 16, 33            | NA ...            | <.01                                          |
| LDL-C level, mg/dL | 104, 37          | 93, 46             | 92, 36            | 97, 33            | .23                                           |
| HDL-C level, mg/dL | 56, 20           | 40, 26             | 45, 18            | 45, 24            | <.01                                          |
| LDL-C level of >160 mg/dL, % | 8 ...            | 5, 3               | 3, 18             | NA ...            | .18                                           |
| HDL-C level of <40 mg/dL, % | 18 ...           | 37, 43             | 43, 0             | NA ...            | .02                                           |
| Clinical variables |                    |                    |                   |                   |                                               |
| BMI, kg/m²       | 29, 12            | 26, 16             | 26, 22            | 27, 6             | .07                                           |
| BMI categories, %| <25                | 26, 32             | 34, 32            | 34, 32            | .05                                           |
| 25–30            | 26, 38             | 45, 37             | 40, 40            | NA ...            | .33                                           |
| >30              | 49, 28             | 30, 28             | 28, 28            | 28, 28            |                                               |
| Weight, kg       | 80, 31            | 72, 22             | 73, 22            | 73, 22            | .06                                           |
| Antiretroviral drugs |                    |                    |                   |                   |                                               |
| Duration of HAART use, years | NA ...           | 7, 3               | 6, 5              | 7, 3              | NA .06                                         |
| No. of PIs used (current), % | 0                | NA ...            | NA ...            | NA ...            | NA .42                                         |
| 1                | NA ...            | 48, 27             | NA ...            | NA ...            |                                               |
| 2                | NA ...            | 28, 18             | NA ...            | NA ...            |                                               |
| Duration of PI use, years | NA ...          | 3.2, 2.9           | 3.1, 4.1          | 2.5, 4.2          | NA .94                                         |
| NRTI use (current), % | NA ...           | NA ...            | NA ...            | NA ...            | NA .42                                         |
| Duration of NRTI use, years | NA ...         | 7.5, 3.9           | 7.3, 3.9          | 6, 6.8            | NA .50                                         |
| NNRTI use (current), % | NA ...           | NA ...            | NA ...            | NA ...            | NA .03                                         |
Table 1. (Continued)

| Characteristics                  | HIV-uninfected women | Treated viremic | Untreated | Treated viremic | All | P, HIV-uninfected vs all HIV-infected women | P across HIV-uninfected and 3 HIV-infected groups |
|----------------------------------|----------------------|----------------|-----------|----------------|-----|---------------------------------------------|-----------------------------------------------|
|                                  | (N = 43)             | (N = 29)       | (N = 41)  | (N = 45)       | (N = 115) |                                             |                                               |
| Duration of NNRTI use, years     | NA ...               | 1.7 2.4       | NA ...    | .6 1.7         | .3 2.4 | NA .07                                       |                                               |
| Adherence to antiretroviral drugs, % | NA ...               | 90 ...         | NA ...    | 72 ...         | 77 ... | NA .03                                       |                                               |
| Abacavir use, %                  | NA ...               | 21 ...         | NA ...    | 22 ...         | 14 ... | NA .88                                       |                                               |
| **CVD risk factors**             |                      |                |           |                |       |                                             |                                               |
| History of diabetes, %           | 33 ...               | 17 ...         | 15 ...    | 31 ...         | 22 ... | .15 .15                                      |                                               |
| Diabetes medication use, %       | 16 ...               | 0 ...          | 7 ...     | 9 ...          | 6 ...  | .046 .12                                     |                                               |
| Lipid-lowering drug use, %       | 2 ...                | 10 ...         | 5 ...     | 7 ...          | 7 ...  | .26 .53                                      |                                               |
| Family history of CAD, %         | 13 ...               | 12 ...         | 29 ...    | 15 ...         | 19 ... | .41 .20                                      |                                               |
| Hypertension, %                  | 44 ...               | 38 ...         | 39 ...    | 42 ...         | 40 ... | .63 .94                                      |                                               |
| Hepatitis C antibody positive, % | 40 ...               | 41 ...         | 44 ...    | 59 ...         | 49 ... | .30 .32                                      |                                               |
| Current smoking, %               | 70 ...               | 34 ...         | 49 ...    | 57 ...         | 48 ... | .01 .17                                      |                                               |
| Race, %                          | Other                | 9 ...          | 14 ...    | 2 ...          | 11 ... | 8 ... .85                                     |                                               |
|                                  | Hispanic             | 23 ...         | 31 ...    | 27 ...         | 26 ... | 28 ...                                       |                                               |
|                                  | African American     | 67 ...         | 55 ...    | 71 ...         | 63 ... | 63 ...                                       |                                               |

**NOTE.** P-values were derived using the Kruskal-Wallis test for continuous variables and $\chi^2$ test for categorical variables. BMI, body mass index; CAD, coronary artery disease; CVD, cardiovascular disease; HAART, highly active antiretroviral therapy; HDL-C, high-density lipoprotein cholesterol; IQR, interquartile range; LDL-C, low-density lipoprotein cholesterol; NA, not applicable; NNRTI, nonnucleoside reverse transcriptase inhibitor; PI, protease inhibitor.

- a PI use includes any use of ritonavir.
- b Adherence was defined by self-report as taking >95% of the prescribed dose.
- c Hypertension was defined as systolic blood pressure of $\geq 140$ mm Hg, diastolic blood pressure of $\geq 90$ mm Hg, or prior diagnosis of hypertension. Dyslipidemia was defined as LDL-C level of $<160$ mg/dL or HDL-C level of $\leq 40$ mg/dL. Diabetes was defined as fasting plasma glucose level of $>126$ mg/dL or prior diagnosis of diabetes mellitus with or without the use of antidiabetic medications. Family history of coronary disease was defined as a female first-degree relative with myocardial infarction or angina before age 65 or male first-degree relative with myocardial infarction or angina before age 55.
after adjustment for viral load and other potential confounders. The association of CD4\(^+\) T cell activation with carotid lesions was attenuated after further adjustment for CD4\(^+\) T cell count (adjusted prevalence ratio_lesions 1.1; 95% CI, .6–2.1) and after adjustment for the ratio of CD4\(^+\) T cells to CD8\(^+\) T cells (adjusted prevalence ratio_lesions, 1.5; 95% CI, .8–2.6). In contrast, the association between CD8\(^+\) T cell activation and carotid lesions remained after adjustment for CD4\(^+\) T cell count and ratio of CD4\(^+\) T cells to CD8\(^+\) T cells.

In contrast to the findings among HIV-infected women, we did not observe an association between T cell activation and increased prevalence of carotid lesions among HIV-uninfected women (Figure 3). Models that included interaction terms provided evidence of effect modification by HIV status, such that higher levels of T cell activation were associated with carotid lesions in the HIV-infected group but not in the HIV-uninfected group (significance tests for interaction, \(P = .06\) for CD4\(^+\) T cell activation and \(P = .02\) for CD8\(^+\) T cell activation).

**CD28\(^-\)CD57\(^+\) T Cells and Subclinical Carotid Artery Disease**

Among HIV-infected women, unadjusted analyses showed a higher frequency of CD8\(^+\)CD28\(^-\)CD57\(^+\) T cells in those with carotid lesions than in those without carotid lesions (\(P = .03\)) (Figure 3). After adjustment for age and use of antiretroviral medications, the prevalence ratio_lesions for each SD change in the percentage of CD8\(^+\)CD28\(^-\)CD57\(^+\) T cells was 1.9 (95% CI, 1.1–3.1; \(P = .01\)) (Table 3). This significant association persisted after further adjustment for CD4\(^+\) T cell count, ratio of CD4\(^+\) T cells to CD8\(^+\) T cells, viral load, and other potential confounders. There were no differences in the frequency of CD4\(^+\)CD28\(^-\)CD57\(^+\) T cells between those with and those without carotid lesions (Figure 3; Table 3). When we repeated the analysis using CD28\(^-\) alone rather than CD28\(^-\)CD57\(^+\) to define T cell subsets, there was an association of CD8\(^+\)CD28\(^-\) T cells but not CD4\(^+\)CD28\(^-\) T cells with carotid lesions (data not shown).

Models that included interaction terms were consistent with the hypothesis that higher levels of CD8\(^+\) T cell senescence were associated with carotid lesions in the HIV-infected group but not in the HIV-uninfected group (significance test for interaction, \(P = .009\)).

In contrast to the findings for the outcome of carotid lesions, cIMT measurements were not associated with T cell activation or senescence markers in either HIV-infected women (Table 3) or HIV-uninfected women (data not shown).

**Multivariate Analyses of T Cell Phenotypes Associated With Subclinical Carotid Artery Disease**

When entered together into a multivariate model, both CD8\(^+\) T cell activation and CD8\(^+\) T cell senescence remained significant or borderline significant in their associations with carotid
Table 2. Association of Clinical Variables With CD38⁺HLA-DR⁺ (Activated) T Cells and CD28⁻CD57⁺ (Senescent) T Cells Among Women With Human Immunodeficiency Virus (HIV) Infection

| Variable                        | Percentage of CD4⁺ CD38⁺DR⁺ T cells | Percentage of CD8⁺ CD38⁺DR⁺ T cells | Percentage of CD4⁺ CD28⁻ CD57⁺ T cells | Percentage of CD8⁺ CD28⁻ CD57⁺ T cells |
|---------------------------------|-------------------------------------|-------------------------------------|---------------------------------------|---------------------------------------|
|                                 | Median IQR P | Median IQR P | Median IQR P | Median IQR P |
| Age, years                     | 40–44      | 7.5 8.9 .85 | 27.5 25.5 .61 | 2.9 5.4 .97    | 34.6 21.6 .83 |
|                                 | 45–49      | 7.7 10.6 | 27.5 17.7 | 2.4 6.0 | 36.7 18.9 |
|                                 | ≥50        | 9.7 10.9 | 31.8 20.1 | 1.9 5.2 | 36.9 18.7 |
| CD4⁺ T cell count, cells/µL     | <200       | 19.4 15.8 <.01 | 33.9 26.6 <.01 | 3.6 15.0 .52 | 37.7 21.2 .40 |
|                                 | 200–349    | 10.4 8.7 | 37.6 21.2 | 3.1 6.3 | 37.1 16.2 |
|                                 | 350–499    | 6.1 3.2 | 27.4 23.9 | 2.0 4.2 | 33.5 21.9 |
|                                 | ≥500       | 4.6 3.1 | 20.6 19.2 | 2.4 5.6 | 31.3 22.5 |
| CD4/CD8 ratio                   | ≤1         | 9.5 10.1 <.01 | 32.3 23.1 <.01 | 2.7 6.0 .37 | 36.8 20.2 .11 |
|                                 | >1         | 3.7 2.2 | 14.7 11.8 | 1.6 4.3 | 29.0 17.7 |
| Prior visits with HIV RNA level | ≤6         | 5.7 6.0 <.01 | 24.3 22.6 .08 | 3.3 5.6 .30 | 35.4 19.4 .74 |
| of >4000 copies/mL              | >6         | 11.2 9.7 | 32.3 20.2 | 2.0 6.3 | 36.3 23.3 |
| HIV RNA, copies/mL              | ≤4000      | 9.0 9.4 <.01 | 25.5 14.7 <.01 | 5.4 6.7 .56 | 35.6 14.6 .98 |
|                                 | 4000–60,000 | 14.6 10.3 | 38.5 16.6 | 8.9 16.6 | 35.4 14.0 |
|                                 | >60,000    | 17.7 13.7 | 40.7 17.5 | 3.4 3.7 | 34.3 12.4 |
| PI use                          | Never      | 8.6 8.5 .40 | 33.5 21.3 .18 | 3.3 5.0 .81 | 38.3 15.9 .51 |
|                                 | <3.3 years | 7.7 15.3 | 26.4 23.3 | 2.1 7.2 | 33.1 18.4 |
|                                 | >3.3 years | 7.3 7.9 | 27.1 23.9 | 2.9 6.3 | 33.5 27.1 |
| NRTI use                        | Never      | 6.6 5.8 .46 | 29.9 10.9 .52 | 4.5 5.3 .63 | 42.8 20.8 .62 |
|                                 | ≤6.1 years | 9.4 14.7 | 32.4 33.8 | 2.3 6.7 | 36.6 16.8 |
|                                 | >6.1 years | 7.3 7.5 | 27.1 24.4 | 2.6 6.2 | 33.6 25.2 |
| NNRTI use                       | Never      | 7.3 7.0 .47 | 29.3 20.8 .93 | 3.3 6.7 .42 | 33.5 20.8 .87 |
|                                 | ≤1.9 years | 9.5 10.4 | 27.1 16.0 | 2.3 4.2 | 37.4 23.3 |
|                                 | >1.9 years | 7.1 8.3 | 29.6 32.3 | 2.2 5.1 | 35.6 18.4 |
| Abacavir use                    | Yes        | 8.1 7.3 .99 | 27.1 20.9 .31 | 2.1 4.4 .24 | 30.7 23.4 .54 |
|                                 | No         | 7.4 10.6 | 30.2 23.5 | 2.6 5.9 | 36.6 21.7 |
| Adherence to antiretroviral      | Yes        | 6.9 8.2 .06 | 22.6 26.8 .45 | 2.3 5.9 .73 | 32.8 15.8 .28 |
| medications                     | No         | 11.6 7.8 | 29.3 14.8 | 2.9 5.0 | 42.5 23.4 |
| Race/ethnicity                  | African American | 4.0 4.2 <.01 | 24.8 15.8 <.03 | .6 4.6 .05 | 38.6 16.5 .02 |
|                                 | Hispanic   | 9.5 13.1 | 36.7 29.3 | 3.8 8.4 | 38.4 17.3 |
|                                 | White or other | 7.8 8.6 | 28.9 21.7 | 2.0 6.1 | 31.9 19.1 |
| Smoking                         | Current    | 7.5 9.1 .79 | 27.4 19.1 .54 | 2.1 5.9 .22 | 31.8 17.8 |
|                                 | Past       | 7.9 10.0 | 32.8 27.3 | 4.0 5.0 | 40.6 19.7 |
|                                 | Never      | 7.5 10.4 | 24.9 31.6 | 1.5 6.3 | 35.8 20.7 |
Table 2. (Continued)

| Variable                      | Percentage of CD4<sup>+</sup> CD38<sup>+</sup>DR<sup>+</sup>T cells Median | IQR | P  | Percentage of CD8<sup>+</sup> CD38<sup>+</sup> DR<sup>+</sup> T cells Median | IQR | P  | Percentage of CD4<sup>+</sup> CD28<sup>-</sup>CD57<sup>+</sup> T cells Median | IQR | P  | Percentage of CD8<sup>+</sup>CD28<sup>-</sup>CD57<sup>+</sup> T cells Median | IQR | P  |
|-------------------------------|-----------------------------|----|----|-----------------------------|----|----|-----------------------------|----|----|-----------------------------|----|----|
| Hepatitis C                   | Yes                         | 7.5| 8.5| .99                        |    |    | 28.2| 17.0 | .61                        |    |    | 2.0 | 5.1 | .23                        |    |    | 36.8| 23.6 | .87                        |    |    |
|                               | No                          | 7.9| 11.3| .99                      |    |    | 30.9| 30.0 | 3.1                      |    |    | 3.1 | 6.6 | .99                        |    |    | 35.6| 19.4 | .99                        |    |    |
| Hypertension                  | Yes                         | 7.5| 12.1| .24                      |    |    | 27.6| 26.2 | .86                      |    |    | 2.0 | 4.8 | .88                        |    |    | 37.3| 24.5 | .71                        |    |    |
|                               | No                          | 7.9| 7.6 | .99                      |    |    | 30.3| 22.2 | 2.8                      |    |    | 2.8 | 6.7 | .99                        |    |    | 34.3| 17.0 | .99                        |    |    |
| Diabetes                      | Yes                         | 7.7| 10.4| .43                      |    |    | 23.2| 15.0 | .13                      |    |    | 1.6 | 6.0 | .37                        |    |    | 33.6| 18.7 | .32                        |    |    |
|                               | No                          | 7.4| 8.9 | .43                      |    |    | 30.2| 23.7 | 2.4                      |    |    | 2.4 | 5.7 | .99                        |    |    | 35.6| 21.6 | .99                        |    |    |
| BMI                           | <25                         | 7.5| 6.9 | .20                      |    |    | 30.3| 24.1 | .41                      |    |    | 2.8 | 6.2 | .25                        |    |    | 32.3| 19.6 | .66                        |    |    |
|                               | 25–30                       | 9.8| 10.8| .99                      |    |    | 28.1| 22.3 | 1.9                      |    |    | 1.9 | 4.3 | .99                        |    |    | 36.8| 24.7 | .99                        |    |    |
|                               | >30                         | 6.4| 9.7 | .99                      |    |    | 27.6| 28.6 | 4.7                      |    |    | 4.7 | 6.5 | .99                        |    |    | 37.2| 15.2 | .99                        |    |    |
| Diabetes medication use       | Yes                         | 13.2| 18.4| .35                      |    |    | 26.1| 21.8 | .79                      |    |    | 4.3 | 8.3 | .99                        |    |    | 31.1| 28.5 | .75                        |    |    |
|                               | No                          | 7.7| 9.0 | .35                      |    |    | 29.3| 26.0 | 2.4                      |    |    | 2.4 | 5.9 | .99                        |    |    | 36.0| 21.1 | .99                        |    |    |
| Lipid-lowering drug use       | Yes                         | 6.2| 6.2 | .07                      |    |    | 19.7| 18.8 | .08                      |    |    | 6.7 | 2.9 | .05                        |    |    | 33.9| 11.2 | .70                        |    |    |
|                               | No                          | 7.9| 10.6| .99                      |    |    | 29.1| 23.2 | 2.3                      |    |    | 2.3 | 5.6 | .99                        |    |    | 36.3| 22.9 | .99                        |    |    |
| Family History of CAD        | Yes                         | 7.3| 8.4 | .69                      |    |    | 29.5| 15.3 | .70                      |    |    | 1.9 | 5.6 | .87                        |    |    | 43.2| 15.5 | .13                        |    |    |
|                               | No                          | 7.9| 9.2 | .69                      |    |    | 28.2| 21.9 | 2.7                      |    |    | 2.7 | 6.3 | .99                        |    |    | 33.5| 19.6 | .99                        |    |    |
| HDL-C level, mg/dL           | <40                         | 9.6| 10.4| .07                      |    |    | 36.7| 28.1 | <.01                     |    |    | 1.6 | 4.9 | .09                        |    |    | 38.4| 21.4 | .03                        |    |    |
|                               | >40                         | 6.2| 8.6 | .07                      |    |    | 25.7| 22.2 | 3.5                      |    |    | 3.5 | 6.2 | .09                        |    |    | 32.6| 19.6 | .09                        |    |    |
| LDL-C level, mg/dL           | <160                        | 7.4| 10.7| .87                      |    |    | 29.1| 24.3 | .17                      |    |    | 2.6 | 5.9 | .69                        |    |    | 36.3| 21.6 | .33                        |    |    |
|                               | >160                        | 9.5| 7.8 | .87                      |    |    | 12.8| 24.6 | 2.3                      |    |    | 2.3 | 8.2 | .69                        |    |    | 31.1| 28.3 | .69                        |    |    |
| Weight, kg<sup>a</sup>       | <73                         | 9.0| 12.0| .24                      |    |    | 30.3| 24.5 | .10                      |    |    | 2.0 | 5.0 | .05                        |    |    | 34.3| 25.4 | .52                        |    |    |
|                               | >73                         | 6.5| 9.2 | .24                      |    |    | 27.4| 21.3 | 3.3                      |    |    | 3.3 | 6.1 | .05                        |    |    | 37.2| 17.9 | .05                        |    |    |

**NOTE.** P values were derived using the (nonparametric) Wilcoxon and Kruskal-Wallis tests. BMI, body mass index; CAD, coronary artery disease; HDL-C, high-density lipoprotein cholesterol; IQR, interquartile range; LDL-C, low-density lipoprotein cholesterol; NNRTI, nonnucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; PI, protease inhibitor.

<sup>a</sup> Values presented represent those above or below the median value. For use of antiretroviral medication, categories were defined as never and 2 categories of ever use with total observed duration of use either below or above the median duration in the drug user group.
lesions. When mutually adjusted in the same model, the prevalence ratio for each SD change in the percentage of CD8\(^+\)CD38\(^+\)HLA-DR\(^+\) T cells was 1.9 (95% CI, 1.1–3.2; \(P = .02\)), and the prevalence ratio for each SD change in the percentage of CD8\(^+\)CD28\(^-\)CD57\(^+\) T cells was 1.6 (95% CI, .9–2.8; \(P = .09\)).

We also examined CD4\(^+\) and CD8\(^+\) T cell activation simultaneously in relation to carotid lesions. When entered into Figure 3.

**Table 3. Multivariate Associations of T Cell Activation and Senescence Markers With Subclinical Carotid Artery Disease Among Women With Human Immunodeficiency Virus (HIV) Infection**

| Variable | Adjusted for age and current use of antiretroviral medications | Also adjusted for HIV RNA level |
|----------|---------------------------------------------------------------|---------------------------------|
|          | Effect estimate | 95% confidence interval | \(P\) | Effect estimate | 95% confidence interval | \(P\) |
| \(PR_{lesions}\) for each SD increase in T cell marker |                  |                              |      |                  |                              |      |
| CD4\(^+\)CD38\(^+\)HLA-DR\(^+\) T cells | 1.6               | 1.1–2.2                       | .02  | 1.6               | 1.1–2.3                       | .02  |
| CD8\(^+\)CD38\(^+\)HLA-DR\(^+\) T cells | 2.0               | 1.2–3.3                       | <.01 | 2.0               | 1.2–3.3                       | <.01 |
| CD4\(^+\)CD28\(^-\)CD57\(^+\) T cells | 1.1               | .8–1.6                        | .64  | 1.1               | .8–1.6                        | .61  |
| CD8\(^+\)CD28\(^-\)CD57\(^+\) T cells | 1.9               | 1.1–3.1                       | .01  | 1.9               | 1.1–3.1                       | .01  |
| Increase in cIMT for each SD increase in T cell marker |                  |                              |      |                  |                              |      |
| CD4\(^+\)CD38\(^+\)HLA-DR\(^+\) T cells | .001              | −.019 to .019                 | .96  | .001              | −.019 to .021                 | .92  |
| CD8\(^+\)CD38\(^+\)HLA-DR\(^+\) T cells | −.002             | −.022 to .018                 | .81  | −.002             | −.023 to .019                 | .85  |
| CD4\(^+\)CD28\(^-\)CD57\(^+\) T cells | .003              | −.016 to .022                 | .74  | .003              | −.017 to .024                 | .74  |
| CD8\(^+\)CD28\(^-\)CD57\(^+\) T cells | −.006             | −.026 to .014                 | .57  | −.006             | −.027 to .015                 | .58  |

**NOTE.** Measures of T cell activation and T cell senescence were log-transformed. The text describes results after adjustment for CD4\(^+\) T cell count and ratio of CD4\(^+\) T cells to CD8\(^+\) T cells. Additional adjustment for participant characteristics described in Table 1 did not change the results substantially. cIMT, carotid intima-media thickness of the right common carotid artery; \(PR_{lesions}\), prevalence ratio for carotid lesions.
a single model, CD8+ T cell activation remained significantly associated with prevalence of carotid lesions (prevalence ratiolesions, 1.8; 95% CI, 1.0–3.3; \( P = .05 \)), whereas CD4+ T cell activation did not (prevalence ratiolesions\(_T\), 1.2; 95% CI, 0.7–1.8; \( P = .54 \)).

**DISCUSSION**

HIV-infected individuals have an increased risk of CVD, and effective HIV therapy appears to improve CVD risk. We report several findings that suggest possible explanatory mechanisms for the association between HIV infection and vascular disease. First, consistent with prior data [6], HIV infection was associated with markedly elevated levels of activated (CD38\(^{+}\)HLA-DR\(^{+}\)) peripheral T cells. Viremic suppression through effective antiretroviral therapy appeared to reduce but not completely reverse this process. Second, among HIV-infected women, T cell activation was associated with markers of subclinical carotid artery disease after adjustment for multiple confounders. Third, CD8+ T cell senescence (phenotypically defined by absence of CD28 and presence of CD57) was also elevated in women with HIV disease, and the frequency of these cells was associated with subclinical carotid artery disease among HIV-infected women. Finally, these associations of T cell activation and senescence with carotid artery parameters were not observed in a population of HIV-uninfected controls who were studied using identical methods and who had comparable cardiovascular risk factor profiles. Collectively, these observations are consistent with a model in which HIV infection results in immune activation, accelerated immunologic aging, and the premature onset of CVD. Effective HIV treatment reduces but may not fully reverse this process.

The ultrasound protocol used in this study was designed to capture several different carotid artery parameters. Among HIV-infected women, T cell activation and senescence were associated with the presence of carotid lesions, defined as focal thickening (>1.5 mm) of the intima-media layer. These lesions typically form at branch points in the internal carotid artery and the carotid bifurcation, where turbulent blood flow evokes elaboration of vascular cellular adhesion molecule-1 and other inflammatory mediators [13]. In contrast, we found no association between T cell activation and mean cIMT of the common carotid artery, a region that is not prone to the development of symptomatic lesions. Longitudinal data show that common carotid artery wall thickness progresses more rapidly in patients with HIV infection who have poor viral control [14], although some prior studies have shown a stronger association of HIV disease with lesions in the internal carotid artery and carotid bifurcation than with common carotid artery thickness [15]. We speculate on potential explanations for these observations. Because of regional hemodynamics, the internal and bifurcation regions of the carotid may be more prone to the development of inflammation-related vascular lesions. Patients with other inflammatory conditions such as rheumatoid arthritis and systemic lupus erythematosus also appear to have normal common carotid cIMT but increased prevalence of carotid artery lesions [16, 17]. Alternatively, localized infection of vascular tissues by HIV [18] or other pathogens might produce focal lesions in the absence of generalized carotid artery wall thickening. It remains unclear whether the observed differences across carotid segments are biologically important or due to technical aspects of our cross-sectional imaging protocol. Although we lacked data on the coronary vasculature, a recent report demonstrated a high prevalence of obstructive coronary artery lesions among HIV-infected adults (6.5% vs 0% in controls) who had no known history or symptoms of coronary disease [19].

Multivariate analyses appeared to suggest that CD8+ T cell activation had the more robust association with carotid lesions when both CD4+ and CD8+ T cell activation were modeled simultaneously. Mouse models of atherosclerosis (eg, low-density lipoprotein receptor knockout [LDLR\(^{-/-}\)] mice and apolipoprotein E knockout [ApoE\(^{-/-}\)] mice) have more clearly implicated CD4+ T cells than CD8+ T cells in atherogenesis [8]. However, as recently hypothesized by Andersson and colleagues [8], CD8+ T cells may become atherogenic in response to intracellular infections even if they are not involved in atherogenesis in normal circumstances. Notably, comparisons of our HIV-infected women with an HIV-uninfected control group suggested a weaker or null association of T cell activation with subclinical carotid artery disease in the absence of HIV infection. This may suggest that direct vascular effects of pathogens affecting HIV-infected individuals, or perhaps HIV itself, contributed to the association of immune activation with subclinical carotid artery disease in the HIV-infected group. Alternatively, the lack of significant findings in the HIV-uninfected controls may reflect a threshold of immune activation that is required to demonstrate an association with carotid wall thickness. It should be noted that although the percentage of activated CD4 cells was increased among patients with HIV infection, the absolute number of peripheral T cells may be reduced in HIV infection, and moreover, these measurements only reflect cells circulating in blood [20].

The mechanism whereby HIV causes increased inflammation and T cell activation is an active area of investigation and has important clinical implications for preventing HIV-related infectious and noninfectious (eg, cardiovascular) morbidity. The degree of inflammation and immune activation is thought to be too high to be simply due to expansion of HIV-specific T cells. HIV infected persons are often co-infected with other pathogens, including CMV and the hepatitis viruses. Recent work by our group suggests that CMV may be an important cause of T cell changes in HIV disease, which is of interest given our previous findings that high levels of CMV-specific T cells are associated with increased cIMT [21]. HIV infection results in
dramatic changes to the gut mucosa, which appears to result in increased translocation of microbial products from the gut lumen into the systemic circulation. These changes may increase immune activation and potentially trigger inflammatory and procoagulant mechanisms that increase vascular risk [22]. Finally, irreversible changes in the lymphoid infrastructure—including collagen deposition in lymphatic tissues and loss of thymic function—may also contribute to the inflammatory environment that exists in HIV disease [23].

Immunosenescence is defined as the gradual age-related decline in immune function that contributes to vaccine unresponsiveness and other sequelae among the elderly. Although multiple perturbations to the adaptive and nonadaptive immune system have been reported, the strongest and most consistent correlates of immunosenescence include the oligoclonal expansion of memory effector CD8⁺CD28⁻ T cells and the expansion of CD57-expressing CD8⁺ T cells. These CD28⁻ cells have limited ability to proliferate and are apoptosis-resistant [24]. Similar observations are emerging with regard to CD4⁺ T cells, which also appear to become more oligoclonal and less functional with age, particularly among CMV seropositive persons [9]. As shown elsewhere and confirmed here, untreated HIV infection appears to result in expansion of phenotypically defined immunosenescent T cells. Importantly, we also show that the process of CD8⁺ T cell immunosenescence is not reversed by effective antiretroviral therapy. We further showed that HIV-associated changes in the immunosenescent profile of circulating T cells predicted increased frequency of carotid lesions. This is a novel finding that is consistent with a growing body of evidence. Enriched numbers of CD28⁻ T cells are found in atherosclerotic plaques [25]. In patients with coronary disease, CMV infection contributes to loss of CD28 and telomeric shortening in CD8⁺ T cells, which in turn predicts cardiac dysfunction [11]. CD4⁺CD28⁻ T cells that recognize heat-shock protein 60, an antigen that triggers atherosclerosis in animal models, have been implicated in severity and prognosis of coronary disease [26, 27]. However, the present study of HIV-infected women implicated CD8⁺ T cell senescence but not CD4⁺ T cell senescence in subclinical atherosclerosis. Our data support the emerging hypothesis that T cell subsets expressing markers of immunosenescence and terminal differentiation may be CVD mediators.

Limitations of the present study include its observational study design and the measurement of immune activation and senescence at a single study visit. Use of HIV medications was not guided by our research protocol. However, we were able to control for detailed, prospectively collected longitudinal information on medication history [12]. The HIV-uninfected control group was relatively modest in size. Information on duration of HIV infection was lacking. We did not measure serum biomarkers of inflammatory mediators such as interleukin 6, although we previously reported as part of the WIHS that C-reactive protein did not predict carotid atherosclerosis among HIV-infected women independently of other clinical risk factors [28]. Although the measures of subclinical vascular disease used in this investigation predict incident CVD events in the general population, no studies have validated this assumption in the HIV-infected population, and too few events are available in our cohort to test this assumption.

In conclusion, our data provide further evidence that persistent activation of the immune system is associated with vascular abnormalities among HIV-infected individuals. This relationship was suggested by a small prior study that, unlike the present investigation, did not feature multivariate analyses, did not control for potential confounding effects of HIV-related and CVD-related variables, and lacked an HIV-uninfected control group [29]. These results have important implications for assessment of vascular risk among adults with HIV infection. Additional research is needed to identify the events or exposures in HIV-infected adults that may drive T cell activation and senescence (including immune responses to HIV, co-infections, or bacterial translocation) and, in turn, increase vascular risk.

Funding

This work was supported by the National Institute of Allergy and Infectious Diseases, National Institutes of Health (grant numbers U01-AI-35004, U01-AI-31834, U01-AI-34994, U01-AI-34989, U01-AI-34993, U01-AI-42590; grant P30AI027763 to University of California, San Francisco–Gladstone Institute of Virology and Immunology Center for AIDS Research); the National Institute of Child Health and Human Development (grant number U01-HD-32632); the National Cancer Institute; the National Institute on Drug Abuse; the National Institute on Deafness and Other Communication Disorders; the National Center for Research Resources (grant number U11 RR024131 to the University of California, San Francisco, Clinical and Translational Science Institute); and the National Heart, Lung and Blood Institute (grant numbers 1R01HL095140, 1R01HL083760 to Albert Einstein College of Medicine).

Acknowledgments

Women’s Interagency HIV Study Collaborative Study Group centers (Principal Investigators) are as follows: New York City/Bronx Consortium (Kathryn Anastos); Brooklyn, NY (Howard Minkoff); Washington, DC, Metropolitan Consortium (Mary Young); The Connie Wofsy Study Consortium of Northern California (Ruth Greenblatt); Los Angeles County/Southern California Consortium (Alexandra Levine); Chicago Consortium (Margie Cohen); and Data Coordinating Center (Stephen Gange).

References

1. Currier JS, Taylor A, Boyd F, Dezii CM, Kawabata H, Burkcel B, et al. Coronary heart disease in HIV-infected individuals. J Acquir Immune Defic Syndr 2003; 33:506–12.
2. Bonnet D, Aggoun Y, Szczepanski I, Bellal N, Blanche S. Arterial stiffness endothelial dysfunction in HIV-infected children. AIDS 2004; 18:1037–41.
3. El-Sadr WM, Lundgren JD, Neaton JD, Gordin F, Abrams D, Arduino RC, et al. CD4⁺ count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355:2283–96.
4. Mary-Krause M, Cotte L, Simon A, Partisani M, Costagliola D. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS 2003; 17:2479–86.

5. Norris PJ, Papalardo BD, Caster B, Spotts G, Hecht FM, Busch MP. Elevations in IL-10, TNF-α, IFN-γ from the earliest point of HIV Type 1 infection. AIDS Res Hum Retroviruses 2006; 22:757–62.

6. Hunt PW, Martin JN, Sinclair E, Bredt B, Hagos E, Lampiris H, et al. T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. J Infect Dis 2003; 187:1334–43.

7. Giorgi JV, Hultin LE, McKeating JA, Johnson TD, Owens B, Jacobson LP, et al. Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J Infect Dis 1999; 179:859–70.

8. Anderson J, Libpy P, Hansson GK. Adaptive immunity and atherosclerosis. Clin Immunol 2010 Jan; 134(1):33–46.

9. Fletcher JM, Yukmanovic-Stjic M, Dunne PJ, Birch KE, Cook JE, Jackson SE, et al. Cytomegalovirus-specific CD4+ T cells in healthy carriers are continuously driven to replicative exhaustion. J Immunol 2005; 175:8218–25.

10. Kapit T Cell Activation and Subclinical CVD

11. Spyridopoulos I, Hoffmann J, Aicher A, Brummendorf TH, Doerr HW, Zeiher AM, et al. Increased carotid intima-media thickness in HIV patients is associated with increased cytomegalovirus-specific T-Cell responses. AIDS 2006; 20:2275–83.

12. Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, Rao S, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006; 12:1365–71.

13. Schacker TW, Nguyen PL, Beilman GJ, Wolinsky S, Larson M, Reilly C, et al. Collagen deposition in HIV-1 infected lymphatic tissues and T cell homeostasis. J Clin Invest 2002; 110:1133–9.

14. Azuma M, Phillips JH, Lanier LL. CD28- T lymphocytes: antigenic and functional properties. J Immunol 1993; 150:1147–59.

15. de Boer OJ, Hirsch F, van der Wal AC, van der Loos CM, Das PK, Becker AE, et al. Costimulatory molecules in human atherosclerotic plaques: an indication of antigen specific T lymphocyte activation. Atherosclerosis 1997; 133:227–34.

16. Baker J, et al. Progression of carotid intima-media thickness in a contemporary HIV cohort. Program abstracts of the 17th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, 2010. http://www.retroconference.org/. Accessed 17 December 2010.

17. Roman MJ, Shanker BA, Davis A, Lockshin MD, Sammaritano L, Simantov R, et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003; 349:2399–406.

18. Eugenin EA, Morgello S, Klotman ME, Moseoaan A, Lento PA, Berman JW, et al. Human immunodeficiency virus (HIV) infection in human arterial smooth muscle cells in vivo and in vitro: implications for the pathogenesis of HIV-mediated vascular disease. Am J Pathol 2008; 172:1100–11.

19. Lo J, Abbara S, Shurtleman L, Soni A, Wei J, Rocha-Filho JA, et al. Increased prevalence of subclinical coronary atherosclerosis detected by coronary computed tomography angiography in HIV-infected men. AIDS 2010; 24:243–53.

20. McCune JM. The dynamics of CD4+ T-cell depletion in HIV disease. Nature 2001; 410:974–79.

21. Haue PY, Hunt PW, Sinclair E, Bredt B, Franklin A, Killian M, et al. Increased carotid intima-media thickness in HIV patients is associated with increased cytomegalovirus-specific T-cell responses. AIDS 2006; 20:2275–83.

22. Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, Rao S, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006; 12:1365–71.